LACTOLOGY FOUNDATION

Carbenoxolone combinations excluding psycholeptics (ATC A02BX51) are considered completely unacceptable during breastfeeding, and any combination product should be judged by the most lactotoxic component, which in this class is carbenoxolone itself.file+2

ATC group and indications

Carbenoxolone combinations excluding psycholeptics belong to the group of “other drugs for peptic ulcer and gastroesophageal reflux disease,” classified under ATC code A02BX51.patikaradar+1
Carbenoxolone is a derivative of glycyrrhetinic acid from licorice root, historically used for gastric and duodenal ulcers, esophagitis and painful oral mucosal lesions such as lip sores and mouth ulcers.thekingsleyclinic+1

Pharmacodynamic profile

Carbenoxolone exerts cytoprotective and anti‑inflammatory effects on the gastrointestinal mucosa, promoting ulcer healing and reducing local inflammation.synapse.patsnap+1
It also inhibits 11β‑hydroxysteroid dehydrogenase, effectively potentiating mineralocorticoid activity of endogenous corticosteroids, which contributes to sodium and water retention, hypokalemia and increased blood pressure.drugbank+1

Pharmacokinetics

After oral administration, carbenoxolone is systemically absorbed, with distribution into extracellular fluid and extensive binding to plasma proteins.synapse.patsnap+1
It is metabolized hepatically and excreted mainly via the kidneys, with an elimination half‑life that permits accumulation and delayed onset of typical mineralocorticoid‑like adverse effects such as edema and electrolyte disturbances.thekingsleyclinic+1

Clinical uses in combinations

In A02BX51 combinations, carbenoxolone is usually combined with other gastroprotective or antacid agents to manage peptic ulcer disease, gastritis or reflux‑related conditions.patikaradar+1
The rationale is symptomatic relief and enhancement of mucosal healing, but from a toxico‑lactation standpoint the presence of carbenoxolone dominates the safety profile of the combination.file+1

Maternal adverse effects

Carbenoxolone commonly causes fluid retention, edema, weight increase and can precipitate or aggravate hypertension due to its mineralocorticoid‑like activity.drugbank+1
It may worsen heart failure, impair glycemic control and induce hypokalemia, and it is considered risky in severe hepatic disease because of additional portal and venous pressure increases.thekingsleyclinic+1

Contraindications and precautions

Carbenoxolone is contraindicated in patients with uncontrolled hypertension, overt heart failure, severe renal impairment, active significant edema states and known hypersensitivity to the substance.drugbank+1
Caution is required in hepatic impairment, in elderly patients and in those concurrently treated with drugs affected by potassium balance or fluid status, such as diuretics or cardiac glycosides.synapse.patsnap+1

Drug–drug interactions

Carbenoxolone may reduce the efficacy of antihypertensive drugs due to fluid retention and increased vascular resistance, necessitating dose adjustment or alternative therapy.thekingsleyclinic+1
Its tendency to cause hypokalemia increases the risk of toxicity from cardiac glycosides and can interact unfavorably with loop and thiazide diuretics, while opposing the action of potassium‑sparing diuretics such as spironolactone.synapse.patsnap+1

Toxicity and overdose

Overdose typically amplifies mineralocorticoid‑related toxicity, with prominent edema, severe hypokalemia, metabolic alkalosis and decompensation of heart failure or hypertension.thekingsleyclinic+1
Management is supportive, including drug discontinuation, correction of electrolytes and fluid balance, and treatment of cardiovascular complications, with consideration of intensive monitoring in severe cases.synapse.patsnap+1

Pregnancy safety

No specific FDA pregnancy category is currently assigned for carbenoxolone, and human pregnancy data are limited.iris.who+1
Given its systemic mineralocorticoid effects, potential impacts on maternal blood pressure, edema and uteroplacental perfusion must be considered, and use in pregnancy is generally discouraged unless clear, substantial benefit outweighs risk.iris.who+1

Lactation risk assessment

On your site, carbenoxolone and its combinations are classified in toxico‑lactation category IV, meaning completely inappropriate for use during breastfeeding.file
This strict rating reflects the drug’s systemic activity, lack of reassuring lactation data and the expectation that clinically relevant amounts would transfer into milk and expose the infant to mineralocorticoid‑type toxicity.ncbi.nlm.nih+1

Expected exposure in breastfed infants

Because carbenoxolone is systemically absorbed, protein‑bound but persistent, passage into human milk is considered plausible in the absence of direct quantitative data.ncbi.nlm.nih+1
Given the low therapeutic margin for disturbances in fluid and electrolyte balance in neonates, even moderate exposure could translate into clinically significant edema, hypertension or hypokalemia in a breastfed infant.medsafe+1

Potential neonatal adverse effects

Theoretical and mechanistic concerns include neonatal fluid retention, poor weight gain due to edema, irritability, lethargy and possible blood pressure elevation.medsafe+1
Electrolyte disturbances—particularly hypokalemia—might manifest as feeding difficulties, vomiting, constipation or cardiac rhythm abnormalities, all of which would be difficult to attribute promptly in routine practice.medsafe+1

Clinical recommendations during lactation

Based on the above, the use of carbenoxolone‑containing combinations (A02BX51) during breastfeeding is considered completely unacceptable, and alternative therapies with established lactation safety should be selected.ncbi.nlm.nih+2
If a breastfeeding mother has already received such a combination, immediate discontinuation, clinical assessment of the infant (weight, hydration, blood pressure and electrolytes where feasible) and switch to a safer regimen are advised.iris.who+2

Approach to fixed combinations

When evaluating any A02BX51 fixed‑dose combination in lactating women, the toxico‑lactation risk must be determined by the most hazardous component, which is carbenoxolone in this class.file
Even if co‑components have favorable breastfeeding profiles, the presence of carbenoxolone drives the overall risk classification to the highest category, and the product should be avoided altogether.ncbi.nlm.nih+1

Regulatory and availability notes

According to your local content, there are currently no carbenoxolone‑containing medicinal products from this ATC class registered in Bulgaria.file
Nevertheless, imported products or legacy prescriptions may be encountered, and awareness of their toxico‑lactation profile remains important for counseling and risk minimization.patikaradar+1

Summary for practice

Carbenoxolone combinations excluding psycholeptics (A02BX51) provide gastroprotective benefits but carry significant mineralocorticoid‑type toxicity and lack reassuring lactation data, justifying their placement in the highest toxico‑lactation risk category.drugbank+2
Breastfeeding women should not be treated with these products; when ulcer or reflux therapy is needed, safer alternatives with well‑characterized breastfeeding compatibility should be chosen.medsafe+2